Scarica l'app Stockscreener
83.68
0.77%
0.64
Dopo l'orario di chiusura:
83.68
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EW Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$83.04
Aprire:
$84.6
Volume 24 ore:
5.60M
Relative Volume:
1.08
Capitalizzazione di mercato:
$48.18B
Reddito:
$6.30B
Utile/perdita netta:
$1.07B
Rapporto P/E:
45.46
EPS:
1.8406
Flusso di cassa netto:
$1.09B
1 W Prestazione:
-1.03%
1M Prestazione:
-7.82%
6M Prestazione:
+2.22%
1 anno Prestazione:
+6.61%
Intervallo 1D:
$83.22
$85.51
Intervallo di 1 settimana:
$81.16
$89.08
Portata 52W:
$72.30
$96.29
Edwards Lifesciences Corp Stock (EW) Company Profile
Nome
Edwards Lifesciences Corp
Settore
Industria
Telefono
(949) 250-2500
Indirizzo
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
83.68 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
ABT
Abbott Laboratories
|
107.27 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
346.60 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
86.88 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.06 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-01 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2026-01-09 | Aggiornamento | TD Cowen | Hold → Buy |
| 2025-12-18 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-10-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2025-04-24 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Aggiornamento | Stifel | Hold → Buy |
| 2025-01-16 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Downgrade | Jefferies | Buy → Hold |
| 2024-07-31 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-07-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Downgrade | TD Cowen | Buy → Hold |
| 2024-07-25 | Downgrade | Truist | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-05-14 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-02-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-28 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-03-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Downgrade | Bernstein | Outperform → Underperform |
| 2023-01-30 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Downgrade | Stifel | Buy → Hold |
| 2022-10-28 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Iniziato | Mizuho | Buy |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-29 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Iniziato | Truist | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-03-16 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-27 | Reiterato | Citigroup | Buy |
| 2022-01-27 | Reiterato | Evercore ISI | Outperform |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | Stifel | Buy |
| 2022-01-27 | Reiterato | UBS | Neutral |
| 2021-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-12-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-30 | Reiterato | Deutsche Bank | Hold |
| 2021-07-30 | Reiterato | Jefferies | Buy |
| 2021-07-30 | Reiterato | Morgan Stanley | Overweight |
| 2021-07-30 | Reiterato | Oppenheimer | Outperform |
| 2021-07-30 | Reiterato | Stifel | Buy |
| 2021-07-30 | Reiterato | UBS | Neutral |
| 2021-07-30 | Reiterato | Wells Fargo | Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-04-05 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-11 | Reiterato | Canaccord Genuity | Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Underperform |
| 2020-04-28 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Outperform |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Reiterato | Canaccord Genuity | Buy |
| 2019-09-23 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-24 | Reiterato | BofA/Merrill | Buy |
| 2019-03-18 | Reiterato | Canaccord Genuity | Buy |
| 2019-01-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Iniziato | Deutsche Bank | Hold |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-16 | Iniziato | Barclays | Underweight |
| 2018-10-02 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Downgrade | Guggenheim | Buy → Neutral |
Mostra tutto
Edwards Lifesciences Corp Borsa (EW) Ultime notizie
UBS initiates Edwards Lifesciences stock coverage with buy rating By Investing.com - Investing.com Canada
Form 4 Edwards Lifesciences Corp For: 27 July By Investing.com - Investing.com Nigeria
Edwards Lifesciences CEO Bernard Zovighian sells $245,134 in shares - Investing.com
Form 144 Edwards Lifesciences Corp For: 27 July By Investing.com - Investing.com South Africa
Form 144 Edwards Lifesciences Corp For: 27 July - Investing.com India
EW|Edwards Lifesciences Corp|Price:83.040|Chg%:+0.410 - TradingKey
Edwards Lifesciences (EW)’s TMTT Revenue Surges 47%: Can Rapid Growth Drive the Next Leg of Earnings Expansion? - Yahoo Finance Singapore
Edwards Lifesciences (EW) insider Zovighian details recent $2.83M stock sale in Form 144 - Stock Titan
Edwards Lifesciences Corp (EW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Edwards Lifesciences stock trades steady as TAVR growth supports margins - Ad-hoc-news.de
ETFs Investing in Edwards Lifesciences Corporation Stocks - TradingView
Edwards Lifesciences (EW) Stock Looks Fair On Cash Flow While Earnings Trade At A Premium - Yahoo Finance
Edwards Lifesciences Corp (EW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Edwards Lifesciences Corp (EW) Institutional Confidence - TradingKey
EW|Edwards Lifesciences Corp|Price:82.630|Chg%:-1.185 - TradingKey
Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors - MarketWatch
Edwards posts strong TAVR sales ahead of potential Medicare coverage expansion - MedTech Dive
Why is Edwards Lifesciences stock rallying today? By Investing.com - Investing.com South Africa
Why is Edwards Lifesciences stock rallying today? - Investing.com
Bernstein raises Edwards Lifesciences stock price target on earnings beat - Investing.com
Bernstein raises Edwards Lifesciences stock price target on earnings beat By Investing.com - Investing.com Canada
Edwards Lifesciences (EW) Receives Upgrade from Leerink with New Price Target - GuruFocus
Edwards Lifesciences Reports Strong Q2 2026 Results With 13.6% Sales Growth, Raises Full-Year Guidance - Minichart
Piper Sandler raises Edwards Lifesciences stock price target on earnings beat - Investing.com
Edwards lifts FY26 growth outlook following steady Q2 performance - Yahoo Finance
Edwards Lifesciences Corporatio (EW) Stock Forecasts - Yahoo Finance
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Gain as Oil Prices Decline—Intel, Edwards Life - Benzinga
Edwards' Q2 Earnings & Revenues Top Estimates, Stock Rises - Yahoo Finance
EDWARDS LIFESCIENCES CORP : LEERINK PARTNERS RAISES TO OUTPERFORM FROM MARKET PERFORM; RAISES TARGET PRICE TO $101 FROM $87 - Bitget
Edwards Lifesciences Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
Bernstein Adjusts Price Target on Edwards Lifesciences to $99 From $96, Maintains Market Perform Rating - marketscreener.com
Leerink upgrades Edwards Lifesciences stock rating on TAVR momentum - Investing.com
Edwards Lifesciences stock holds focus on margin and growth - AD HOC NEWS
Leerink upgrades Edwards Lifesciences stock rating on TAVR momentum By Investing.com - Investing.com Canada
Leerink Partners Upgrades Edwards Lifesciences to Outperform From Market Perform, Adjusts PT to $101 From $87 - marketscreener.com
EW|Edwards Lifesciences Corp|Price:83.800|Chg%:-0.570 - TradingKey
Edwards Lifesciences Corp (EW) Q2 2026 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo! Finance Canada
Edwards Lifesciences Corp (EW) Q2 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Advancements - GuruFocus
Edwards Lifesciences Announces Q2 2026 Financial Results Highlighting Market Leadership - Kalkine Media
Edwards Lifesciences (EW) Reports Strong Q2 2026 Sales Growth - GuruFocus
Edwards Lifesciences Q2 Earnings Call Highlights - Yahoo Finance
Edwards Lifesciences earnings up next: TAVR momentum in focus - Investing.com UK
Earnings call transcript: Edwards Lifesciences tops Q2 2026 estimates, lifts sales outlook - Investing.com
Edwards Lifesciences (EW) Reports Strong Q2 Earnings, Raises Rev - GuruFocus
Edwards Lifesciences (EW) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Edwards Lifesciences Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Edwards Lifesciences Jumps After Strong Q2 Growth and Higher 2026 Sales Outlook - Moomoo
Edwards Lifesciences jumps after strong Q2 growth and higher 2026 sales outlook - Quiver Quantitative
Edwards Lifesciences Narrows Full-Year Sales Outlook After Second-Quarter Growth - WSJ
Is Edwards Lifesciences (EW) Undervalued After Q2 Earnings Beat? - GuruFocus
Edwards Lifesciences Q2 Adjusted Earnings, Revenue Rise; Q3 Guidance Set - marketscreener.com
Edwards Lifesciences Corp Azioni (EW) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.89%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):